Molecular mass of semaglutide and why the figure differs between sources posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Worth separating two things this subcategory keeps merging: what the molecule does, which is reasonably well characterised, and what a particular vial contains, which is a documentation question and has nothing to do with pharmacology.
The disagreement above is smaller than it looks once the terms are fixed.
Post #59 put the caveat in the right place and I want to underline it.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
Building on post #63 rather than restating it.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
I would rather say I do not know than round it up to an answer.
Useful. I had the fact and not the reason, which turns out to be the important half.
Where I part company with post #63, and it is a narrow parting.
Taking molecular mass of semaglutide seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
That is all I can say without guessing.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Where I would look next, rather than where I would stop.
Collapsed as off-topic by two members at trust level 3 or above
Adding the measurement that post #67 says would settle it.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
I had written a reply contradicting post #68 and deleted it. Here is what survived.
Where the molecular mass of semaglutide reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
The variance between people here is larger than the effect being discussed.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
Written in the hope of being told what I have missed.
Post #74 is the version of this I will quote in future. One addition.
The most useful thing anyone has posted about molecular mass of semaglutide in this category was a table of what had been measured and by whom. That is what I would want again.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
Following this. I have the same question and no better information than the first post.
Answering the question post #76 raises rather than the one it answers.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
One more caveat and then I will stop qualifying: the sample selected itself.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Adding the caveat now so it does not have to be extracted later.
The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.
Noting that I have skin in this question and have tried to discount for it.
Everything in post #78 holds. The case it does not cover is the one I have.
The reason molecular mass of semaglutide keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Genuinely open to being wrong about this one.
The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
Agreed on all of that, and I have nothing to add to it.
Reading back through the molecular mass of semaglutide threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
This follows post #85 rather than contradicting it.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
I am confident about the direction and much less about the magnitude.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Two people can read the same figure differently here and both be reasonable.
The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.
One of those cases where knowing the mechanism does not help the decision.